Eledon Pharmaceuticals 관리

관리 기준 확인 2/4

Eledon Pharmaceuticals CEO는 DA Gros, Sep2020 에 임명되었습니다 의 임기는 4.17 년입니다. 총 연간 보상은 $ 2.55M, 21.9% 로 구성됩니다. 21.9% 급여 및 78.1% 보너스(회사 주식 및 옵션 포함). 는 € 36.21K 가치에 해당하는 회사 주식의 0.015% 직접 소유합니다. 36.21K. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 5.9 년입니다.

주요 정보

DA Gros

최고 경영자

US$2.6m

총 보상

CEO 급여 비율	21.9%
CEO 임기	4.2yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	3.6yrs
이사회 평균 재임 기간	5.9yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

DA Gros 의 보수는 Eledon Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$25m
Jun 30 2024	n/a	n/a	-US$89m
Mar 31 2024	n/a	n/a	-US$129m
Dec 31 2023	US$3m	US$559k	-US$117m
Sep 30 2023	n/a	n/a	-US$145m
Jun 30 2023	n/a	n/a	-US$145m
Mar 31 2023	n/a	n/a	-US$89m
Dec 31 2022	US$1m	US$533k	-US$88m
Sep 30 2022	n/a	n/a	-US$38m
Jun 30 2022	n/a	n/a	-US$38m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$748k	US$504k	-US$35m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$23m
Dec 31 2020	US$7m	US$150k	-US$23m

보상 대 시장: DA 의 총 보상 ($USD 2.55M )은 German 시장( $USD 787.21K ).

보상과 수익: 회사가 수익성이 없는 동안 DA 의 보상이 증가했습니다.

CEO

DA Gros (52 yo)

4.2yrs

테뉴어

US$2,553,153

보상

Dr. David-Alexandre C. Gros, also known as DA, M.D., Ph D., serves as Chief Executive Officer and Non-Independent Director at Eledon Pharmaceuticals, Inc. since September 09, 2020. Dr. Gros served as an ad...

리더십 팀

이름	위치	테뉴어	보상	소유권
David-Alexandre Gros	CEO & Non Independent Director	4.2yrs	US$2.55m	0.015% € 36.2k
Steven Perrin	President	4.2yrs	US$1.54m	0.0017% € 4.0k
Paul Little	Chief Financial Officer	3.7yrs	US$1.32m	0.017% € 40.2k
John Herberger	Vice President of Technical Operations	2.5yrs	데이터 없음	데이터 없음
Bryan Smith	General Counsel	3.6yrs	US$1.68m	0% € 0
David Hovland	Chief Regulatory Officer	3.6yrs	데이터 없음	데이터 없음
Eliezer Katz	Chief Medical Officer	1.1yrs	데이터 없음	데이터 없음

3.6yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: 2TK 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
David-Alexandre Gros	CEO & Non Independent Director	4.2yrs	US$2.55m	0.015% € 36.2k
Steven Perrin	President	4.2yrs	US$1.54m	0.0017% € 4.0k
Keith Katkin	Independent Chairman of the Board	7.5yrs	US$1.52m	0.0011% € 2.7k
John McBride	Independent Director	7.5yrs	US$371.82k	0% € 0
James Robinson	Independent Director	1.1yrs	US$201.79k	데이터 없음
June Lee	Independent Director	3.9yrs	US$374.44k	0% € 0
Hamid Djalilian	Member of Scientific Advisory Board	5.9yrs	데이터 없음	데이터 없음
Paola Marchisio	Member of Scientific Advisory Board	5.9yrs	데이터 없음	데이터 없음
Tal Marom	Member of Scientific Advisory Board	5.9yrs	데이터 없음	데이터 없음
Michael Pichichero	Member of Scientific Advisory Board	5.9yrs	데이터 없음	데이터 없음
Anne Schilder	Member of Scientific Advisory Board	5.9yrs	데이터 없음	데이터 없음
Seth Pranksy	Member of Scientific Advisory Board	5.9yrs	데이터 없음	데이터 없음

5.9yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: 2TK 의 이사회는 경험(평균 재직 기간 5.9 년)으로 간주됩니다.

Eledon Pharmaceuticals 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024

Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer

Insufficient new directors

Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors

Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023

Chief Financial Officer recently bought €73k worth of stock

Recent updates

New major risk - Revenue and earnings growth

Eledon Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $84.9951 million.

Eledon Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Eledon Pharmaceuticals, Inc. announced delayed 10-Q filing

Eledon Pharmaceuticals, Inc. Provides Enrollment Update for Phase 2 Bestow Trial Assessing Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Presents Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc., Annual General Meeting, Jul 10, 2024

New major risk - Shareholder dilution

Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

Eledon Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1B Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Appoints of Eliezer Katz as Chief Medical Officer

Insufficient new directors

Eledon Pharmaceuticals Appoints Allan Douglas Kirk to Board of Directors

Eledon Pharmaceuticals, Inc. Appoints James Robinson to Its Board of Directors, Effective October 1, 2023

Eledon Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 2 Bestow Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation

Eledon Pharmaceuticals, Inc. Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation

New major risk - Financial position

Eledon Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Eledon Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Eledon Pharmaceuticals, Inc. Receives FDA Clearance of IND Application to Evaluate Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

Eledon Pharmaceuticals Announces the First Patient Dosed in Phase 1B Trial Evaluating Tegoprubart in Kidney Transplantation

Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

Eledon Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2a Trial Evaluating Tegoprubart in IgA Nephropathy

Eledon Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Senior VP of Administration & Principal Accounting Officer Jon Kuwahara has left the company

Chief Financial Officer recently bought €73k worth of stock

Eledon Pharmaceuticals, Inc. Announces Update on Development Strategy for AT-1501 in Renal Transplantation

Eledon Pharmaceuticals, Inc. Announces Appointments of Paul Little as Chief Financial Officer

New 90-day low: €10.50

Eledon Pharmaceuticals, Inc.(NasdaqCM:ELDN) dropped from NASDAQ Composite Index

New 90-day low: €12.50

Novus Therapeutics, Inc. Appoints June Lee to the Board of Directors

Novus Therapeutics, Inc. to Report Q3, 2020 Results on Nov 16, 2020

Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis

New 90-day high: €21.50

Novus Therapeutics, Inc. announced that it has received $108.15 million in funding from a group of investors

Novus Therapeutics, Inc. announced that it expects to receive $108.15 million in funding from a group of investors

New 90-day high - €0.89

Novus Therapeutics, Inc. Announces Resignation of Gregory Flesher as Chief Executive Officer

New 90-day low - €0.31

New 90-day low - €0.35

Novus Therapeutics, Inc.(NasdaqCM:NVUS) dropped from Russell Microcap Value Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령